Serial Endoscopic Variceal Band Ligation for Esophageal Varices Due to Portal Hypertension: A Prospective Observational Study from Southern Rajasthan

Background Esophageal variceal hemorrhage is a major decompensating event in portal hypertension. Endoscopic variceal band ligation (EVBL) controls bleeding by mechanically strangulating varices while avoiding the deeper tissue injury associated with sclerosant injection. Although EVBL is established in acute hemostasis and secondary prevention, the number of sessions required for eradication and the practical pattern of short-term adverse effects may vary with disease severity, referral pathways, and follow-up adherence. This study evaluated serial EVBL in adults treated at a tertiary-care hospital in Udaipur, Rajasthan. Methods This hospital-based prospective observational study included 40 adults with portal hypertension and esophageal varices who underwent EVBL at the American International Institute of Medical Sciences between April 2023 and March 2025. Participants were assessed clinically and with routine laboratory testing and abdominal imaging when indicated. Upper gastrointestinal endoscopy was repeated at four-week intervals, with further EVBL until complete variceal obliteration. Outcomes were summarized using frequencies, proportions, and means. The principal outcomes were number of sessions to obliteration, change in endoscopic grade, recurrence at six months, and procedure-related adverse effects. Results The participants were 31 men and 9 women, aged 31–80 years. Hematemesis was the leading presenting complaint in 20 patients (50.0%), followed by melena in 10 (25.0%). Cirrhosis was the recorded cause of portal hypertension in 31 patients; the reported etiologic distribution was alcohol-associated disease in 21 (52.5% of the cohort), chronic hepatitis B in 11 (27.5%), and non-alcoholic fatty liver disease in 8 (20.0%). Twenty-six patients (64.0%) were Child–Pugh class A, 12 (30.0%) class B, and 2 (6.0%) class C. At baseline, 10 patients had grade I, 16 grade II, and 14 grade III varices. Five patients achieved obliteration by eight weeks and 35 by 12 weeks; the mean number of sessions was 2.875. At six-month endoscopy, 25 patients returned: 18 had no reappearance and 7 underwent repeat EVBL for recurrent varices. Retrosternal pain occurred in 12 patients (30.0%), fever in 4 (10.0%), and hematemesis in 2 (5.0%); no stricture was recorded. Conclusions In this single-centre cohort, serial EVBL achieved documented obliteration in two or three sessions for all patients who completed the eradication protocol, with mostly transient adverse effects. The six-month assessment was limited by loss to follow-up, and recurrence among reviewed patients supports continued surveillance. The findings support a pragmatic four-week EVBL pathway but should not be interpreted as comparative evidence of superiority over pharmacological or shunt-based strategies.

Authors

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11190471/v1
Primary Topic
Liver Disease and Transplantation
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Serial Endoscopic Variceal Band Ligation for Esophageal Varices Due to Portal Hypertension: A Prospective Observational Study from Southern Rajasthan

Shivangi Falwaria
Research Square
Liver Disease and Transplantation
preprint

Serial Endoscopic Variceal Band Ligation for Esophageal Varices Due to Portal Hypertension: A Prospective Observational Study from Southern Rajasthan

Shivangi Falwaria
preprint en

Abstract

Background Esophageal variceal hemorrhage is a major decompensating event in portal hypertension. Endoscopic variceal band ligation (EVBL) controls bleeding by mechanically strangulating varices while avoiding the deeper tissue injury associated with sclerosant injection. Although EVBL is established in acute hemostasis and secondary prevention, the number of sessions required for eradication and the practical pattern of short-term adverse effects may vary with disease severity, referral pathways, and follow-up adherence. This study evaluated serial EVBL in adults treated at a tertiary-care hospital in Udaipur, Rajasthan. Methods This hospital-based prospective observational study included 40 adults with portal hypertension and esophageal varices who underwent EVBL at the American International Institute of Medical Sciences between April 2023 and March 2025. Participants were assessed clinically and with routine laboratory testing and abdominal imaging when indicated. Upper gastrointestinal endoscopy was repeated at four-week intervals, with further EVBL until complete variceal obliteration. Outcomes were summarized using frequencies, proportions, and means. The principal outcomes were number of sessions to obliteration, change in endoscopic grade, recurrence at six months, and procedure-related adverse effects. Results The participants were 31 men and 9 women, aged 31–80 years. Hematemesis was the leading presenting complaint in 20 patients (50.0%), followed by melena in 10 (25.0%). Cirrhosis was the recorded cause of portal hypertension in 31 patients; the reported etiologic distribution was alcohol-associated disease in 21 (52.5% of the cohort), chronic hepatitis B in 11 (27.5%), and non-alcoholic fatty liver disease in 8 (20.0%). Twenty-six patients (64.0%) were Child–Pugh class A, 12 (30.0%) class B, and 2 (6.0%) class C. At baseline, 10 patients had grade I, 16 grade II, and 14 grade III varices. Five patients achieved obliteration by eight weeks and 35 by 12 weeks; the mean number of sessions was 2.875. At six-month endoscopy, 25 patients returned: 18 had no reappearance and 7 underwent repeat EVBL for recurrent varices. Retrosternal pain occurred in 12 patients (30.0%), fever in 4 (10.0%), and hematemesis in 2 (5.0%); no stricture was recorded. Conclusions In this single-centre cohort, serial EVBL achieved documented obliteration in two or three sessions for all patients who completed the eradication protocol, with mostly transient adverse effects. The six-month assessment was limited by loss to follow-up, and recurrence among reviewed patients supports continued surveillance. The findings support a pragmatic four-week EVBL pathway but should not be interpreted as comparative evidence of superiority over pharmacological or shunt-based strategies.

Research Square
Good health and well-being
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon